



MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (ADM)



In December 2010, a White House memorandum from the Assistant to the President for Homeland Security and Counterterrorism tasked the Secretary of Defense to:


“Establish agile and flexible advanced development and manufacturing capabilities to support the development, licensure, and manufacturing of medical countermeasures.”

OVERVIEW

- Multi-product, multi-suite biomanufacturing facility
- Contractor-owned, contractor-operated (Ology Bioservices)
- cGMP compliant/BSL-3 capable
- Can support up to 4 distinct products at once
- Established FDA Known Technologies / Platforms (mAb, DNA, Vero Cell)
- Maximum flexibility through rapid changeover and reconfiguration
- Additional Capacity & Fill/Finish (end-to-end capability) anticipated to be online mid 2021

WHY THE DEPARTMENT OF DEFENSE (DoD)?

- Priority access for DoD emergency requirements
- Capitalizes on interdependencies between DoD and HHS
- Provides scalability and surge capacity for DoD needs



SUPPORT TO COVID-19 RESPONSE

DNA VACCINE

Activity: Ology Bioservices is actively working with Inovio Pharmaceuticals to manufacture their DNA vaccine for the prevention of infection from the COVID-19 virus. The program aims to rapidly and efficiently deliver over 150,000 doses of vaccine for use by DoD personnel by the end of CY2020.

Government Partners

- Office of the Assistant Secretary of Defense for Health Affairs
- Defense Health Agency
- Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Industry Partners

- Ology Bioservices
- Inovio Pharmaceuticals

Funding: Provided by Defense Health Agency



MONOCLONAL ANTIBODY

Activity: Ology Bioservices has worked with Vanderbilt University Medical Center to discover monoclonal antibody candidates for prevention and treatment of infection from the COVID-19 virus. Ology continues to develop and manufacture these candidates to rapidly and efficiently deliver over 10,000 doses for DoD personnel by the end of CY2020.

Government Partners

- Office of the Assistant Secretary of Defense for Health Affairs
- Defense Health Agency
- Defense Advanced Research Projects Agency
- Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Industry Partner

- Ology Bioservices

Academic Partner:

- Vanderbilt University Medical Center

Funding: Provided by Defense Health Agency